Anti-PIGA Antibody (N462/29)

Catalog No.

RHE21602

Host species

Mouse

Isotype

IgG2a, kappa

Clonality

Monoclonal

Target

Phosphatidylinositol N-acetylglucosaminyltransferase subunit A, Phosphatidylinositol-glycan biosynthesis class A protein, PIG-A, GlcNAc-PI synthesis protein, PIGA

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Applications

IHC, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

N462/29

The Advancing Landscape of Paroxysmal Nocturnal Hemoglobinuria Treatment., PMID:40257298

Insights from comparison of serum IgG4 between T2-eosinophilic asthma and eosinophilic granulomatosis with polyangiitis/idiopathic hypereosinophilic syndrome., PMID:40201966

Mepolizumab versus benralizumab for eosinophilic granulomatosis with polyangiitis (EGPA): A European real-life retrospective comparative study., PMID:40147217

Crovalimab: a new era in paroxysmal nocturnal hemoglobinuria management., PMID:40110253

The role of Anti-PAD4, Anti-CarP, and Anti-RA33 antibodies combined with RF and ACPA in predicting abatacept response in rheumatoid arthritis., PMID:39815378

Induction of Tier 2 HIV-Neutralizing IgA Antibodies in Rhesus Macaques Vaccinated with BG505.664 SOSIP., PMID:39772048

Impact of metabolism-related markers on outcomes in ovarian cancer patients: Findings of the MITO16A/MaNGO-OV2 trial., PMID:39513196

Clinical Characteristics of Anti-Synthetase Syndrome: Analysis From the Classification Criteria for Anti-Synthetase Syndrome Project., PMID:39467037

Navigating the Complement Pathway to Optimize PNH Treatment with Pegcetacoplan and Other Currently Approved Complement Inhibitors., PMID:39273426

Anifrolumab in Refractory Systemic Lupus Erythematosus: A Real-World, Multicenter Study., PMID:38950957

Agreement between local and central anti-synthetase antibodies detection: results from the Classification Criteria of Anti-Synthetase Syndrome project biobank., PMID:38488094

Edible Plant-Derived Extracellular Vesicles for Oral mRNA Vaccine Delivery., PMID:38400183

ANCA-negative EGPA: only eosinophils without vasculitis? Insights from anti-T2 biologics., PMID:38090592

Effects of cytotoxic T-lymphocyte-associated protein 4 compared to TNF inhibitors on lipid profile: Results from an observational multicentre rheumatoid arthritis cohort., PMID:37956778

Flow cytometry-based quantification of genome editing efficiency in human cell lines using the L1CAM gene., PMID:37943774

Effect of anti-P ribosomal and anti-NR2 antibodies on depression and cognitive processes in SLE: an integrated clinical and functional MRI study., PMID:37918951

Comparison of clinical features between patients with anti-synthetase syndrome and dermatomyositis: results from the MYONET registry., PMID:37698987

Brain-reactive autoantibodies in neuropsychiatric systemic lupus erythematosus., PMID:37383228

Health-related quality of life in patients with β-thalassemia: Data from the phase 3 BELIEVE trial of luspatercept., PMID:37095595

Novel Molecular Therapies and Genetic Landscape in Selected Rare Diseases with Hematologic Manifestations: A Review of the Literature., PMID:36766791

Intracellular immunoglobulin A (icIgA) in protective immunity and vaccines., PMID:36597220

Quantification of Tumor and Angiogenesis-Related Markers in Ovarian Cancer Models by a Digital Pathology Approach., PMID:36161409

Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial., PMID:36007538

Evaluating ravulizumab for the treatment of children and adolescents with paroxysmal nocturnal hemoglobinuria., PMID:35502699

Lights on HBME-1: the elusive biomarker in thyroid cancer pathology., PMID:35444029

Correction of a CD55 mutation to quantify the efficiency of targeted knock-in via flow cytometry., PMID:35420385

Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies., PMID:35200123

An Italian Multicenter Study on Anti-NXP2 Antibodies: Clinical and Serological Associations., PMID:35092577

Intravenous immunoglobulin as an important adjunct in the prevention and therapy of coronavirus 2019 disease., PMID:34940980

Immunoglobulin A Glycosylation and Its Role in Disease., PMID:34687019

Rab11-FIP1 and Rab11-FIP5 Regulate pIgR/pIgA Transcytosis through TRIM21-Mediated Polyubiquitination., PMID:34638806

Ineffective Erythropoiesis in β-Thalassaemia: Key Steps and Therapeutic Options by Drugs., PMID:34281283

[Novel therapeutics for paroxysmal nocturnal hemoglobinuria]., PMID:34108330

[Current treatment of paroxysmal nocturnal hemoglobinuria and prospects for new therapeutic agents in the future]., PMID:34108318

CD52/GPI- T-Cells Are Enriched for Alloreactive Specificity and Predict Acute Graft-Versus-Host-Disease After Stem Cell Transplantation., PMID:33863699

Standard protocol for the PIGRET assay, a high-throughput reticulocyte Pig-a assay with an immunomagnetic separation, used in the interlaboratory trial organized by the Mammalian Mutagenicity Study Group of the Japanese Environmental Mutagen and Genome Society., PMID:33743813

Biologics and Targeted Synthetic Drugs Can Induce Immune-Mediated Glomerular Disorders in Patients with Rheumatic Diseases: An Updated Systematic Literature Review., PMID:33595833

Elevated Endostatin Expression Is Regulated by the pIgA Immune Complex and Associated with Disease Severity of IgA Nephropathy., PMID:33341801

Upregulation of microRNA‑140‑3p mediates dachshund family transcription factor 1 expression in immunoglobulin A nephropathy through cell cycle‑dependent mechanisms., PMID:33313942

Paroxysmal nocturnal haemoglobinuria (PNH): novel therapies for an ancient disease., PMID:33190263

Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial., PMID:33087150

Mutations in PIGA cause a CD52-/GPI-anchor-deficient phenotype complicating alemtuzumab treatment in T-cell prolymphocytic leukemia., PMID:32875608

Broadly Neutralizing Antibodies for Influenza: Passive Immunotherapy and Intranasal Vaccination., PMID:32751206

A Rare Case of Paroxysmal Nocturnal Hemoglobinuria With Bilateral Renal Vein Thrombosis., PMID:32724752

Consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria., PMID:32713742

Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria., PMID:32430502

Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting., PMID:32275125

A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia., PMID:32212518

Paroxysmal nocturnal hemoglobinuria: Test to monitor the action of eculizumab treatment., PMID:32202389

Detection of Pig-a Mutant Erythrocytes in the Peripheral Blood of Rats and Mice., PMID:31989564

Document Download

Anti-PIGA Antibody (N462/29).pdf